WCLC 2025 - Posters & ePosters-P1.07.48 Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC With High-Risk Pathological Factors

P1.07.48 Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC With High-Risk Pathological Factors

Asset Subtitle

Xiao-Long Li

Meta Tag

Speaker Xiao-Long Li

Topic Early-Stage Non-small Cell Lung Cancer